Cohort study
Are β-blockers necessary for patients with heart failure with preserved ejection fraction? PURSUIT-HFpEF registry
- Registry-based cohort study (subgroup analysis)
- inverse probability of treatment weighting
Authors' conclusion
In HFpEF patients without AF or IHD, β-blocker use was associated with higher mortality-related risk
Study context
- Population
- Patients with HFpEF in the PURSUIT-HFpEF registry, divided by atrial fibrillation (AF) and/or ischaemic heart disease (AF/ischaemic heart disease (IHD)) vs neither (non-AF/IHD)AF/IHD n = 687
- Exposure
- β-blocker users vs non-users, by AF/IHD status
Main finding
As reported in the abstract
Outcomes by subgroup (inverse probability of treatment weighting (IPTW)-weighted)
β-blocker vs non-β-blockerHazard ratio (95% CI)P value
non-AF/IHD: all-cause death
1.448(1.007–2.082)
P = 0.046non-AF/IHD: cardiac death
2.380(1.406–4.027)
P = 0.001non-AF/IHD: cardiac composite outcomes
1.441(1.018–2.039)
P = 0.039Observational data: associations, not effects.
Original publication
Are β-blockers necessary for patients with heart failure with preserved ejection fraction? PURSUIT-HFpEF registry. Eur J Heart Fail. Published 11 March 2026. doi:10.1093/ejhf/xuag071
Summarised from the published abstract; every number is checked against it